Core Viewpoint - Rosen Law Firm is reminding investors who purchased or sold Cepton, Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline on December 8, 2025 [1] Group 1: Class Action Details - Investors who engaged in transactions of Cepton common stock between July 29, 2024, and January 6, 2025, may be eligible for compensation without incurring out-of-pocket fees through a contingency fee arrangement [2] - To participate in the class action, interested parties can visit the provided link or contact the law firm for more information [3][6] - A lead plaintiff must file a motion with the Court by December 8, 2025, to represent other class members in the litigation [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action litigation [4] Group 3: Case Allegations - The lawsuit alleges that Cepton's management made materially false and misleading statements regarding the company's business and operations during the Class Period [5] - Specific claims include the failure to disclose a credible third-party bid valuing Cepton at more than double the Koito Acquisition, and the Board's lack of meaningful exploration of this offer [5]

Core Points - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Western Alliance Bancorporation due to allegations of materially misleading business information [1] - A class action is being prepared by Rosen Law Firm to seek recovery of investor losses without any out-of-pocket fees for those who purchased Western Alliance Bancorporation securities [2] - Western Alliance Bancorporation's stock fell by 10.88% on October 16, 2025, following the disclosure of a lawsuit against Cantor Group V LLC for fraud related to collateral loans [3] Company Background - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4] - The firm has been consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of MoonLake Immunotherapeutics during the specified Class Period of the upcoming lead plaintiff deadline on December 15, 2025 [1]. Group 1: Class Action Details - Investors who bought MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][6]. - A lead plaintiff must file a motion with the Court by December 15, 2025, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action litigation [4]. Group 3: Case Allegations - The complaint alleges that during the Class Period, defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of James Hardie Industries plc during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][5]. Group 1: Class Action Details - Investors who bought James Hardie common stock between May 20, 2025, and August 18, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 23, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized for its performance in securities class action settlements [4]. Group 3: Case Background - The lawsuit alleges that James Hardie Industries misled investors regarding the performance of its North America Fiber Cement segment, falsely claiming strong demand while being aware of distributor destocking [5].

Core Viewpoint - Rosen Law Firm is encouraging investors of Telix Pharmaceuticals Ltd. to secure legal counsel before the January 9, 2026 deadline for a securities class action lawsuit related to the company's misleading statements during the class period from February 21, 2025 to August 28, 2025 [1][5]. Group 1: Class Action Details - Investors who purchased Telix securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by January 9, 2026 [3][6]. - The lawsuit alleges that Telix made materially false and misleading statements regarding its prostate cancer therapeutic candidates and the quality of its supply chain, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise and success in this area [4].

New York, New York--(Newsfile Corp. - November 18, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Stride, Inc. (NYSE: LRN) between October 22, 2024 and October 28, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 12, 2026.SO WHAT: If you purchased Stride a securities during the Class Pe ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Synopsys, Inc. securities between December 4, 2024, and September 9, 2025, of the December 30, 2025, deadline to become lead plaintiffs in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Synopsys securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by December 30, 2025, to serve as lead plaintiff [2] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] Group 2: Case Allegations - The lawsuit alleges that Synopsys made materially false and misleading statements and failed to disclose adverse facts about its business and operations [4] - Specific claims include that Synopsys' focus on artificial intelligence customers was negatively impacting the economics of its Design IP business and that certain decisions were unlikely to yield intended results [4] - The lawsuit asserts that these undisclosed issues had a material negative impact on financial results, leading to misleading positive statements about the company's prospects [4]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Tandem Diabetes Care securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to the misleading information [2]. Group 2: Company Incident and Stock Impact - On August 7, 2025, Tandem Diabetes Care announced a voluntary medical device correction for select t:slim X2 insulin pumps due to a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following this announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked highly for the number of settlements [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is reminding purchasers or sellers of Cepton, Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline on December 8, 2025 [1]. Group 1: Class Action Details - Investors who bought or sold Cepton common stock between July 29, 2024, and January 6, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, interested parties can visit the provided link or contact the law firm for more information [3][6]. - A lead plaintiff must file a motion with the Court by December 8, 2025, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action litigation [4]. Group 3: Case Allegations - The lawsuit alleges that Cepton's management made materially false and misleading statements regarding the company's business and operations during the Class Period [5]. - Specific claims include that Cepton received a credible third-party bid valuing the company at more than double the Koito Acquisition, which was not adequately disclosed to shareholders [5]. - The failure to disclose this information deprived shareholders of the opportunity to make informed decisions regarding the Koito Acquisition [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Avantor, Inc. common stock during the specified class period of the upcoming lead plaintiff deadline on December 29, 2025 [1]. Group 1: Class Action Details - Investors who bought Avantor common stock between March 5, 2024, and October 28, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [3][6]. - A lead plaintiff must file a motion with the court by December 29, 2025, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 and has been consistently ranked among the top firms for securities class action settlements since 2013 [4]. Group 3: Case Allegations - The lawsuit alleges that Avantor's management misrepresented the company's competitive position and failed to disclose negative impacts from increased competition, leading to materially false and misleading statements about the company's business and prospects [5].